Fred Khosravi
Fred Khosravi, Confluent Surgical's Chairman, is currently President of Access Closure Incorporated. Mr. Khosravi was Co-Founder and President of Embolic Protection Inc. (EPI), now a division of Boston Scientific Corporation. Both Confluent Surgical and EPI are companies spun-off of Incept LLC, a technology incubator in which Mr. Khosravi and Dr. Amar Sawhney are both Managing Directors. Prior to that Mr. Khosravi founded EndoTex Interventional Systems, a Cupertino, CA based company which is developing minimally invasive solutions for treatment of carotid artery disease where he was the company's CEO through December 1997, and Chairman through August 1999. Mr. Khosravi has 18 years of experience in the medical device business and has previously held key management positions with Focal, Inc., Guidant Corporation, and Alcon Surgical, Inc.

Sandra Panem, Ph.D.
Sandra Panem, Ph.D. joined Cross Atlantic Partners in 2000 as a partner. Previously, she was President of Vector Fund Management, where she was responsible for the start-up, capital raising, and management of the asset management affiliate of Vector Securities International. Operations included the management of the Vector Later-Stage Equity Fund, L.P., and Vector Later-Stage Equity Fund II, L.P., private partnerships committing $240 million to equity investments in the emerging life science and healthcare industries. Prior to joining Vector, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a $200 million mutual fund that invested in public and private biotechnology companies. Prior to Oppenheimer, Dr. Panem was Vice President at Salomon Brothers, Inc. where she acted as a member of Salomon Brothers Venture Capital, a $40 million fund focused on early and later-stage life science and technology investments. Dr. Panem was also an Assistant Professor at the University of Chicago, a Fellow at the Brookings Institution, and is the author of several books and papers concerning the commercialization of new medical technologies. Currently, she holds directorships in Martek Biosciences Corporation (MATK), AirLogix Corporation, Acorda Pharmaceuticals Corp., Synaptic Pharmaceuticals (SNAP), and Bioject (BJCT). She is also a Governor of the New York Academy of Sciences. Dr. Panem received a B.S. Degree in Biochemistry ('66) and a Ph.D. in Microbiology ('70) from the University of Chicago.

Amar Sawhney, Ph.D. - Co-Founder, President and CEO
Amar Sawhney, Ph.D. is one of the inventors of the hydrogel technology, which forms the core of Confluent's technology platform. His inventions have formed the basis for the founding of several medical device and biotechnology companies and their products. In addition, other companies that are pursuing technologies that have been co-invented by Dr. Sawhney include Access Closure, Inc. (ACI), Novacell, and Azopax. Dr. Sawhney holds over 55 patents and has authored over 100 publications and scientific abstracts. Prior to co-founding Confluent, Dr. Sawhney was Director and Technology Founder at Focal, Inc. (acquired by Genzyme). In addition to Confluent, he serves on the board of MarketRx Inc. (an Incept company specializing in sales and marketing effectiveness, planning, and analytical products and services) as well as ACI.

Martin Sutter
Martin Sutter is a founding Managing Director of Essex Woodlands Health Ventures, LLC, and has more than 25 years of management experience in operations, marketing and finance in the chemical and life sciences industries. Mr. Sutter helped to create the first formal biomedical technology transfer venture in Texas, Cardiovascular Systems (Amnion) in 1985, and subsequently has co-founded more than a half dozen companies originating from institutions within The Texas Medical Center. Mr. Sutter has lead investments and participated on the Boards of Directors of over 30 public and private life science companies. Mr. Sutter was previously affiliated with Mitchell Energy & Development Corporation (MEDC) where he was involved in chemical engineering, operations and marketing, and subsequently, was President of The Woodlands Venture Capital Company, a wholly owned subsidiary of MEDC. He subsequently privatized the program in 1988-1989 with the formation of The Woodlands Venture Fund, L.P. where he was Managing General Partner. Prior to that, he was with Peat Marwick Mitchell & Company. Trained in chemical engineering and finance, Mr. Sutter received a Bachelor of Science degree from LSU, an MBA from the University of Houston and is also a CPA.

William Tidmore
William Tidmore is the past President and Chairman of Depuy Acromed. He was also President of Depuy, the world's oldest orthopedic company, which was acquired by Johnson and Johnson in 1999. Over 14 years at Depuy, Mr. Tidmore held various senior management positions including responsibilities for international businesses with direct operational responsibilities in several countries across Europe, Latin America, Japan, and Canada. He was instrumental in the acquisition of Acromed by Depuy. Prior to that Mr. Tidmore was at Ethicon, Inc. a J&J company, where he held several management responsibilities including Vice President of Sales and Marketing in Canada. Mr. Tidmore holds a Marketing degree from the University of Georgia.

Mark A. Wan
Mark Wan is a founding General Partner of Three Arch Partners. Prior to co-founding Three Arch Partners, Mr. Wan was a general partner at Brentwood Associates. During his 16 years in venture capital, Mr. Wan has emphasized working with entrepreneurs in very early stage companies. He has often assumed temporary operating responsibilities, managing key functions during a company's young life. He has served on the boards of many private and public medical companies including Biopsys Medical, Odyssey Healthcare, and Perclose. Mr. Wan has a BS in Engineering and a BA in Economics from Yale University. He also holds an MBA from the Stanford Graduate School of Business.

Charles Warden
Charles Warden is a Managing Director at Versant Ventures, where he focuses on medical device investments. Before joining Versant, he was a General Partner with Schroder Ventures Life Sciences. Previously Mr. Warden worked with Boston Capital Ventures where he concentrated on medical device and healthcare investments, prior to which he was a consultant with Monitor Company, a strategy-consulting firm. He has served on the boards of numerous companies and is presently a director of Acufocus Inc, CardioFocus Inc., Concentric Medical Inc., Insulet Corporation, Liposonix Inc, and Sadra Medical Inc. Mr. Warden is also actively involved with The Innovation Factory, a medical devices incubator. Mr. Warden received his Bachelor’s degree from Beloit College and obtained an MBA from Harvard Business School.